Systematic Analysis of Stress Granule Regulators-Associated Molecular Subtypes Predicts Drug Response, Immune Response, and Prognosis in Non-Small Cell Lung Cancer

被引:4
作者
Wang, Dan [1 ,2 ]
Ao, Jiangen [1 ]
Xiong, Youwen [3 ]
Zhang, Xinyi [4 ]
Zhang, Weifang [1 ]
机构
[1] Nanchang Univ, Dept Pharm, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
[2] Fudan Univ, Shanghai Engn Res Ctr Ind Microorganisms, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China
[3] Jiangxi Ctr Med Device Testing, Dept Testing, Nanchang, Jiangxi, Peoples R China
[4] Nanchang Univ, Dept Resp Dis, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
来源
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2022年 / 10卷
基金
中国国家自然科学基金;
关键词
non-small cell lung cancer; stress granule; molecular subtypes; drug response; immune response; prognosis; RNA-BINDING PROTEINS; ERBB FAMILY BLOCKER; PI3K/AKT/MTOR PATHWAY; EFFICACY; GROWTH; INHIBITORS; PHASE; KEYNOTE-024; METASTASES; DISCOVERY;
D O I
10.3389/fcell.2022.868918
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Lung cancer has the world's second highest cancer incidence and second highest cancer-related mortality rate. However, the mechanism underlying non-small cell lung cancer (NSCLC) remained to be unclear. Overall, this study for the first time revealed Stress Granule Regulators were mutated and dysregulated in NSCLC samples by analyzing TCGA database. Moreover, three subtypes of NSCLC were identified based on the expression levels of Stress Granule Regulators. Patients in cluster 2 showed a higher survival rate than those in clusters 1 and 3. Bioinformatics analysis indicated the cell cycle, mTOR signaling pathway, EGFR signaling, PI3K/Akt signaling and DNA damage repair signaling were significantly related to molecular subtypes. Moreover, we performed a prediction analysis of the response to the inhibitors against the aforementioned signaling. Our results showed patients in C2 NSCLC had the highest sensitivity to MK.2206 (AKT.inhibitor) and Rapamycin (mTOR inhibitor). Patients in C3 NSCLC had the highest sensitivity for Temsirolimus (PI3K/mTOR signaling), BIBW2992 (EGFR signaling), Erlotinib (EGFR signaling), PD.0332991 (CDK4/6 inhibitor), CGP.60474 (CDK inhibitor), and Gefitinib (EGFR signaling). Moreover, our results showed patients in C1 NSCLC had the highest sensitivity to AKT.inhibitor, AZD6482 (PI3K inhibitor). To evaluate the response to immune therapy of different subtypes, we analyzed the tumor immune inflation, immune regulators expression, and TIDE score in different SG related subtypes. These results showed that C2 and C3 may be more sensitive to immune therapy. To better predict the prognosis of NSCLC, we analyzed the correlation between stress granule regulator expression and overall survival time in NSCLC and constructed a Stress Granule Score including EIF2S1, CTSG, EIF4G1, IGF2BP1, PABPC1 to predict the prognosis of NSCLC. Overall, this study for the first time uncovers the effect of stress particles on drug response, immune response, and prognosis, laying a new theoretical foundation for the NSCLC prognosis and treatment.
引用
收藏
页数:17
相关论文
共 50 条
  • [11] Glasgow prognostic score predicts prognosis of non-small cell lung cancer: a meta-analysis
    Zhu, Lucheng
    Chen, Sumei
    Ma, Shenglin
    Zhang, Shirong
    SPRINGERPLUS, 2016, 5
  • [12] Systematic profiling of chemotherapeutic drug response to EGFR gatekeeper mutation in non-small cell lung cancer
    Yao, Jun
    Zhao, Xiaojuan
    Ding, Xi
    COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2016, 64 : 126 - 133
  • [13] AP-4 predicts poor prognosis in non-small cell lung cancer
    Gong, Hai
    Han, Shaorong
    Yao, Hui
    Zhao, Hui
    Wang, Yanming
    MOLECULAR MEDICINE REPORTS, 2014, 10 (01) : 336 - 340
  • [14] Tertiary Lymphoid Structures, Immune Response, and Prognostic Relevance in Non-Small Cell Lung Cancer
    Giatromanolaki, Alexandra
    Chatzipantelis, Paschalis
    Contrafouris, Constantinos A.
    Koukourakis, Michael, I
    CANCER INVESTIGATION, 2023, 41 (01) : 48 - 57
  • [15] Decreased SARI expression predicts poor prognosis of Chinese patients with non-small cell lung cancer
    Zhou, Ren-Jie
    Shi, Zhong
    Zhou, Kun
    Wang, Hai-Dong
    Zhang, Guo-Qiang
    Li, Xue-Tao
    Xu, Jian-Ping
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2013, 6 (10): : 2056 - 2063
  • [16] Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy
    Hoerner-Rieber, Juliane
    Bernhardt, Denise
    Dern, Julian
    Koenig, Laila
    Adeberg, Sebastian
    Paul, Angela
    Heussel, Claus Peter
    Kappes, Jutta
    Hoffmann, Hans
    Herth, Felix J. P.
    Debus, Juergen
    Warth, Arne
    Rieken, Stefan
    RADIOTHERAPY AND ONCOLOGY, 2017, 125 (02) : 317 - 324
  • [17] Analysis of the response and toxicity to gefitinib of non-small cell lung cancer
    Konishi, J
    Yamazaki, K
    Kinoshita, I
    Isobe, H
    Ogura, S
    Sekine, S
    Ishida, T
    Takashima, R
    Nakadate, M
    Nishikawa, S
    Hattori, T
    Asahina, H
    Imura, M
    Kikuchi, E
    Kikuchi, J
    Shinagawa, N
    Yokouchi, H
    Munakata, M
    Dosaka-Akita, H
    Nishimura, M
    ANTICANCER RESEARCH, 2005, 25 (1B) : 435 - 441
  • [18] EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Hastings, K.
    Yu, H. A.
    Wei, W.
    Sanchez-Vega, F.
    DeVeaux, M.
    Choi, J.
    Rizvi, H.
    Lisberg, A.
    Truini, A.
    Lydon, C. A.
    Liu, Z.
    Henick, B. S.
    Wurtz, A.
    Cai, G.
    Plodkowski, A. J.
    Long, N. M.
    Halpenny, D. F.
    Killam, J.
    Oliva, I
    Schultz, N.
    Riely, G. J.
    Arcila, M. E.
    Ladanyi, M.
    Zelterman, D.
    Herbst, R. S.
    Goldberg, S. B.
    Awad, M. M.
    Garon, E. B.
    Gettinger, S.
    Hellmann, M. D.
    Politi, K.
    ANNALS OF ONCOLOGY, 2019, 30 (08) : 1311 - 1320
  • [19] Impact of bone metastasis on prognosis in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
    Zhu, Yonghua
    She, Jingyao
    Sun, Rong
    Yan, Xinxin
    Huang, Xinyao
    Wang, Peijuan
    Li, Bo
    Sun, Xiangdong
    Wang, Changqing
    Jiang, Kai
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [20] A signature of tumor immune microenvironment genes associated with the prognosis of non-small cell lung cancer
    Li, Jia
    Li, Xin
    Zhang, Chenyue
    Zhang, Chenxing
    Wang, Haiyong
    ONCOLOGY REPORTS, 2020, 43 (03) : 795 - 806